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Analysis of renal function after aneurysm repair
with a device using suprarenal fixation (Zenith
AAA Endovascular Graft) in contrast to open
surgical repair
Roy K. Greenberg, MD,a Timothy A. M. Chuter, MD,b Michael Lawrence-Brown, MD,c Stephan
Haulon, MD,a and Lori Nolte, PhD,d for the Zenith Investigators, Cleveland, Ohio; San Francisco, Calif; Perth,
Australia; and West Lafayette, Ind
Purpose: This study was undertaken to assess the effect on renal function of open surgery and endovascular abdominal
aortic aneurysm (AAA) repair with suprarenal fixation with the Zenith device.
Methods: Data for 279 patients with similar preoperative comorbid conditions were prospectively analyzed after AAA
repair. One hundred ninety-nine patients underwent endografting with the Zenith AAA Endovascular Graft, which
incorporates suprarenal fixation (Zenith standard risk group, ZSR), and 80 patients underwent open surgery (standard
surgical risk group, SSR). Endovascular repair was also performed in 100 patients considered poor candidates for open
repair (Zenith high risk group, ZHR). Serum creatinine concentration (SCr) and anatomic defects were assessed before
the procedure, before discharge, and at 1, 6, 12, and 24 months in all patients who underwent endovascular repair, and
before the procedure and at 1 and 12 months in patients who underwent open surgical repair (only SCr was measured
before discharge). Renal function was also analyzed, with a creatinine clearance calculation (Cockcraft-Gault). Renal
insufficiency was defined as an increase in SCr greater than 30% from a preoperative baseline value, any SCr concentration
in excess of 2.0 mg/dL, or any need for dialysis. Cumulative renal infarction and arterial occlusion rates were calculated
with computed tomographic, ultrasonographic, and angiographic data, and reported as cumulative values.
Results: Despite the initially superior renal function in the ZSR group at the pre-discharge evaluation (P .01), there were
no differences at 12 months with respect to rise in SCr greater than 30% (ZSR, 16%, vs SSR, 12%; P  .67), SCr rise
greater than 2.0 mg/dL (ZSR, 2.5%, vs SSR, 3.4%; P .66), incidence of renal artery occlusion (ZSR, 1%, vs SSR, 1.4%;
P > .99), or infarction (ZSR, 1.5%, vs SSR, 1.4%; P > .99). Only one patient in each group required hemodialysis. Of
note, both groups of patients demonstrated a reduction in creatinine clearance over 12 months, which then stabilized or
improved by 24 months for ZSR patients.
Conclusions: Renal dysfunction occurs in a subset of patients regardless of type of repair (open or endovascular with
suprarenal fixation). The cause of renal dysfunction after open or endovascular repair with a suprarenal stent is probably
multifactorial. The observed dysfunction occurs in a small number of patients, and the effect in the endovascular group
(no data for the surgical group at 24 months) appears to be transient. The initial dysfunction, apparent in both groups
over 12 months of follow-up, stabilizes or improves at 12 to 24 months. (J Vasc Surg 2004;39:1219-28.)Renal dysfunction ranks third in frequency of morbid-
ity after open abdominal aortic aneurysm (AAA) repair,1
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doi:10.1016/j.jvs.2004.02.033and remains a strong predictor of poor survival.2 The only
independent risk factor that has been linked with the devel-
opment of postoperative renal failure after infrarenal AAA
repair is preoperative renal insufficiency.3 Despite caution
with respect to administration of intravenous contrast me-
dium immediately before repair, the addition of intraoper-
ative diuretic agents and free radical scavengers, and careful
attention to clamp time and location, the incidence of acute
renal failure remains significant.1,4 The cause of renal dys-
function after AAA repair has been attributed to atheroem-
bolism (mural thrombus or atheromatous debris), renal
ischemia, intraoperative hypotension, and technical issues
related to the renal arteries. Similar problems have been
noted after endovascular repair.5,6 Morbidity remains sig-
nificant despite the lack of aortic clamping, and may be
exacerbated by the need for administration of intravenous
contrast medium.
The desire to fixate endovascular prostheses in the
suprarenal aorta mandates placement of a transrenal stent.
The effect of wire forms traversing the renal ostia has been1219
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dysfunction. However, the suprarenal aorta has also been
cited as more stable, with respect to late dilation and
incidence of atherosclerotic disease, and thus may be a
more durable fixation site for prostheses.7 This study was
undertaken to compare the effects on the kidneys of type of
repair, that is, open repair or endovascular stent grafting
with a device that incorporates a suprarenal fixation system
with barbs. This article presents a detailed analysis of data
pertaining to renal dysfunction from the US multicenter
Zenith trial.
MATERIAL AND METHODS
A prospective, multicenter, nonrandomized study was
conducted in an effort to evaluate the safety and effective-
ness of the Zenith AAA Endovascular Graft. Patient enroll-
ment began in January 2000, and was completed in July
2001. Fifteen centers in the United States participated
(Table I, online only), and their respective institutional
review boards approved the clinical protocol and patient
consent forms. Study groups included two subsets of phys-
iologically similar patients, one group treated with an en-
dovascular device (Zenith standard risk group, ZSR) and
the other group treated with conventional surgery (stan-
dard surgical risk group, SSR). Two additional patient
groups were assessed. Patients with pathophysiologic con-
ditions that placed them at high risk for open repair,
including chronic renal insufficiency and preoperative renal
artery stenosis, also received the Zenith AAA Endovascular
Graft, but were enrolled in a separate study arm (Zenith
high risk group, ZHR). In addition, centers were allowed
to enroll up to six patients in a roll-in group (Zenith roll-in
group, ZRI) to accumulate experience with the device
before accrual of pivotal data. Imaging studies were inde-
pendently analyzed by a core laboratory (The Cleveland
Clinic Peripheral Vascular Core Laboratory). All imaging
results reported here refer to core laboratory data unless
otherwise stated. Renal events noted by the clinical sites
without core laboratory corroboration are also reported.
Additional oversight was provided by a clinical events com-
mittee, which reviewed and adjudicated all serious adverse
events and deaths, and by an independent data safety
monitoring board. Details of the device and multicenter
trial are discussed elsewhere.8 The specific issue discussed
here is the transrenal fixation system.
The suprarenal component of the Zenith endoprosthe-
sis is constructed from 0.018-inch stainless steel wire. The
uncovered component is 26 mm long, and contains 10 to
12 struts (for graft diameter 28 mm, 10 struts; for graft
diameter 28 mm, 12 struts). Each strut has a 5-mm long
barb, 0.0093 inch in diameter, oriented caudally and at-
tached in a staggered configuration with a wire wrap and
solder. The suprarenal component is attached with a mono-
filament suture to the proximal aspect of the polyester graft
material. Four gold markers located approximately 1.5 mm
inferior to the proximal aspect of the graft material denote
the region of the graft that is intended for placementimmediately below the renal arteries; magnified and radio-
graphic views are shown in Fig 1, online only.
The techniques of the endovascular and open proce-
dures have been described.9,10 Assessment of renal func-
tion in patients undergoing endovascular repair included
measurement of serum creatinine concentration (SCr) pre-
operatively, as well as postoperatively before discharge
(within 7 days), at 30 days, and at 6, 12, and 24 months.
Assessment of renal artery patency and the presence of new
renal infarcts was accomplished with computed tomo-
graphic (CT) analysis at follow-up visits and supplemented
with site data including ultrasonographic or angiographic
studies. In patients who underwent open surgery SCr was
measured before the procedure, before discharge, and at 30
days and 12 months after the procedure, and CT scans were
obtained preoperatively and at 30 days and 12 months.
Renal dysfunction was defined in a manner that was
more sensitive than in many previous publications.11-13
Specifically, a rise in SCr was considered significant if it
exceeded the baseline value by 30% and surpassed an abso-
lute level of 2.0 mg/dL. Renal patency was determined by
the continuity of the contrast material between the aorta
and primary renal artery. The presence of renal infarcts was
assessed and differentiated from normal parenchyma and
renal cysts at each CT follow-up visit with three-phase CT
studies. Anatomic data reported are cumulative. Creatinine
clearance, according to the Cockcraft-Gault formula,14 was
calculated at each time point in all patients. Data for any
patients undergoing secondary interventions to treat renal-
related problems, patients requiring hemodialysis, or pa-
tients with graft impingement noted on any follow-up
studies were analyzed further, and are reported.
Each study arm was analyzed separately with respect to
change in mean SCr, creatinine clearance, and mean per-
cent change in creatinine clearance at each time point. In
addition, data for patients in the ZSR group with preoper-
ative renal dysfunction were further analyzed. Comparisons
between groups were made with the Student t test. Mean
SCr over time was assessed with a multivariate repeated
measures analysis of variance.
A description of the repair technique, as well as device
sizing and design is provided in the Appendix, online only.
RESULTS
A total of 351 patients (ZSR group, 199; ZHR group,
100; ZRI group, 52) underwent successful placement of
the Zenith AAA Endovascular Graft, and 79 patients sur-
vived open surgical repair. Mean patient age was 71 years,
and approximately 90% of patients were men (Table II,
online only). Mean procedure time was 154  56 minutes
in all endovascular groups, and 239  92 minutes in the
SSR group. Mean contrast material dose was 162 77 mL
in the ZSR group, 156  77 mL in the ZHR group, and
160  95 mL in the ZRI group. Although the number of
patients in whom renal dysfunction developed, as measured
by an increase in SCr of 30% or more (Table III), was
notable in both study arms (ZSR group, 16%; SSR group,
12%), development of SCr in excess of 2.0 mg/dL in these
as mi
JOURNAL OF VASCULAR SURGERY
Volume 39, Number 6 Greenberg et al 1221patients was uncommon (ZSR group, 2.5%; SSR group,
3.4%). Multivariate repeated measures analysis of variance
showed that the mean SCr was higher at the 12-month
follow-up examination compared with the pre-procedure
(baseline) value in all study groups (ZSR, P .001; SSR,
P  .004; ZHR, P  .001; ZRI, P  .06). This change
remained relatively constant between groups; there was no
appreciable difference (P .96) in mean SCr at 12 months
between ZSR and SSR groups. However, the time of onset
of renal dysfunction differed among the groups. There was
a lower incidence of elevated SCr (30%) in the ZSR group
compared with the SSR group before discharge (P  .01),
an improvement that was not sustained through the 12-
month follow-up (P  .68), nor was it present (P  .07)
when patients requiring suprarenal clamping were excluded
from the SSR group.
Creatinine clearance was calculated for all groups with
the Cockcroft-Gault equation, and graphically expressed as
a mean percent change from baseline over time. The com-
parison of ZSR and SSR groups is depicted in Fig 2, which
demonstrates no intergroup differences. The observed de-
crease from baseline creatinine clearance in both ZSR and
SSR groups though 12 months appeared to improve in the
ZSR group at 24 months. The subset of patients with any
evidence of worsening renal function, manifested by an
increase in SCr greater than 30%, is shown in Fig 3. (See
Table III. Mean serum creatinine concentration and incid
ZSR SSR
Baseline
Mean SCr 1.13  0.02
(n  199)
1.15  0
(n  8
Pre-discharge
Mean SCr 1.05  0.02
(n  199)
1.13  0
(n  7
% With renal dysfunction 2.5
(5/198)
10
(8/79
Mean SCr: 30 d 1.18  0.03
(n  184)
1.21  0
(n  6
% With renal dysfunction 9.8
(18/183)
6.1
(4/66
Mean SCr: 6 mo 1.22  0.04
(n  170)
NA
% With renal dysfunction 13
(22/170)
NA
Mean SCr: 12 mo 1.26  0.04
(n  174)
1.26  0
(n  6
% With renal dysfunction 16
(28/174)
13
(8/61
Mean SCr: 24 mo 1.20  0.04
(n  120)
NA
% With renal dysfunction 20
(25/120)
NA
ZSR, Zenith standard risk group; SSR, surgical standard risk group; ZHR, Z
*As measured by increase in SCr concentration30% over baseline. The ZR
either ZSR or ZHR.
†After removal of all patients in the SSR group in whom suprarenal clamps w
SSR groups (P  .07). No other changes in statistical relationships were n
subsets. Roll-in patients are not included in this table, because that group walso Fig 4, online only, for individual patient information.)
As in Fig 2, the nadir of the graphically depicted creatinine
clearance was reached at 12 months, with a moderate
rebound noted at 24 months in the ZSR group.
Specific factors that may have been associated with
renal failure were also analyzed. Comparisons were made to
evaluate the potential detrimental effects of suprarenal
clamping in the SSR group, a technique required in 18% of
the surgical patients (14 of 80). SCr elevation greater than
30% before discharge was detected in 7.7% of patients (5 of
65) in whom infrarenal clamps were used, and 21% of
patients (3 of 14) in whom suprarenal clamps were required
(P  .14). However, by 30 days, values had returned to
baseline in two of the three patients with renal dysfunction
in the suprarenal clamp group. Renal failure requiring
dialysis developed in one patient with an infrarenal clamp,
but in no patients with suprarenal clamps. In one surgical
patient with a suprarenal clamp postoperative renal artery
occlusion developed, and later a renal artery infarct was
noted at the 12-month follow-up examination; no imme-
diate postoperative contrast-enhanced study was per-
formed in this patient, because of an elevated SCr. With the
exception of the pre-discharge comparison, similarities and
differences between the ZSR and SSR groups were sus-
tained even after removal of all patients in the SRS group in
whom a suprarenal clamp was used. There was no statistical
of renal dysfunction*
P
SSR (only
infrarenal
clamps) P ZHR
.65 1.13  0.04
(n  65)
.94 1.41  0.10
(n  100)
.09 1.11  0.06
(n  64)
.29 1.32  0.09
(n  100)
.01† 7.8
(5/64)
.07 4.0
(4/100)
.69 1.21  0.08
(n  54)
.63 1.60  0.12
(n  92)
.45 7.4
(4/54)
.79 17
(16/92)
NA NA NA 1.56  0.15
(n  76)
NA NA NA 13
(10/76)
.96 1.27  0.05
(n  51)
.84 1.60  0.12
(n  76)
.68 12
(6/51)
.51 14
(11/76)
NA NA NA 1.47  0.10
(n  53)
NA NA NA 13
(7/53)
high-risk group; SCr, serum creatinine concentration; NA, not available.
up is not reported because it consisted of a mix of patients who qualified for
ced during open repair, there was no statistical difference between ZSR and
hen ZSR group was compared with SSR group without suprarenal clamp
xed, including both patients at standard and at high medical risk.ence
.03
0)
.05
9)
)
.07
6)
)
.05
1)
)
enith
I gro
ere pla
oted w
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ZSR and SSR groups before discharge, in the absence of
any patients with suprarenal clamps (ZSR, 2.5%, vs SSR,
7.8%; P  .07).
Patients with a diagnosis of renal artery occlusion or
renal infarction through 12 months are presented in Table
IV. No differences in cumulative incidence of renal artery
occlusion (ZSR, 1.0% vs SSR, 1.4%; P  .99) or renal
Fig 2. Mean percent change in predicted (Cockcroft-G
surgical risk (SSR) and Zenith standard risk (ZSR) group
ZSR and SSR groups at 12 months. Trend toward impro
reach statistical significance (P  .51)
Fig 3. Mean percent change in predicted (Cockcroft-G
than 30% rise in serum creatinine concentration from b
between the Zenith standard risk (ZSR) and standard
creatinine clearance in ZSR group between 12 and 24
provides reassurance of renal function stabilization. Grap
this figure is depicted in Fig 4, online only.infarction (ZSR, 1.5% vs SSR, 1.4%; P  .99) were de-
tected. No additional infarcts or occlusions were detected
through 24 months in the ZSR and ZHR groups. How-
ever, one renal artery occlusion was noted after 12 months
in a patient in the ZRI group. In this patient graft material
impinged on the renal artery ostium after initial endograft
deployment. SCr in this patient increased from a baseline
value of 0.8 mg/dL to a peak of 1.6 mg/dL at 30 days, and
quation) creatinine clearance for all patients in standard
e nearly identical change in creatinine clearance between
nt in creatinine clearance from 12 to 24 months did not
equation) creatinine clearance for patients with greater
e at 12 months. Renal dysfunction was nearly identical
cal risk (SSR) groups at 12 months. Improvement in
ths did not reach statistical significance (P  .06), but
each ZSR group patient included in the calculation forault e
s. Not
vemeault
aselin
surgi
mon
h for
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formed. Including this patient, nine patients within the
endovascular cohort had graft material that impinged on
renal ostia (ZSR, 6; ZHR, 2; ZRI, 1). The incipient arterial
defect was recognized during the initial procedure in four
of the nine patients, three of which were successfully treated
at the time of endograft implantation with concomitant
Table IV. Diagnosed renal artery occlusion or renal paren
Study group First noted
Renal artery occlusion
ZSR 6 mo Graft deployed
appreciated
resulted in r
SSR† 12 mo‡ Proximal graft
immediately
arteries
ZHR 6 mo (partial
occlusion)
Preexisting co
elevated SC
progressed t
ZRI 24 mo Graft material
artery ostium
occlusion
Renal parenchymal infarct
ZSR Pre-discharge Intentional em
accessory re
ZSR 12 mo Intentional co
accessory re
ZSR 6 mo Graft deployed
appreciated
SSR† 12 mo‡ Proximal graft
immediately
arteries
ZHR Pre-discharge Intentional co
renal artery
ZRI Pre-discharge 80% renal ar
procedure
SCr, Serum creatinine concentration; ZSR, Zenith standard risk; SSR, surgi
*Left renal artery angioplasty with stent placement; right renal artery occlu
†Suprarenal clamping used during procedure.
‡No pre-discharge or 30-day CT scan available, and per protocol no 6-mon
Fig 5. Chart of patients (9/351) who underwent endov
artery. This figure reinforces the importance of assessin
impingement on the renal ostia.renal stent placement or caudal tension on the endopros-
thesis, without any measurable change in SCr. Three of the
five patients, in whom the problem was not recognized
during the initial implantation procedure, underwent treat-
ment of the renal arteries subsequent to the initial operative
procedure; the outcomes of these events are depicted in Fig
5.
al infarct
se SCr Intervention
high, not
cedure;
nfarct
30% rise; not 2.0
mg/dL
Yes*
tomosis
w both renal
30% rise; 2.2 mg/dL No
ive heart failure;
-procedure;
odialysis
30% rise; 7.5 mg/dL;
progressed to renal
failure
No
ging on renal
gressed to total
30% rise; not 2.0
mg/dL
No
ation of
tery
30% rise; not 2.0
mg/dL
No
e of small
tery
Stable (1.0–1.1 mg/dL) No
high, not
cedure
30% rise; not 2.0
mg/dL
Yes*
tomosis
w both renal
30% rise; 2.2 mg/dL No
e of accessory 30% rise; 6.5 mg/dL;
progressed to renal
failure
No
tenosis pre- 30% rise; not 2.0
mg/dL
No
ndard risk; ZHR, Zenith high risk; ZRI, Zenith roll-in.
performed.
ar treatment in whom graft material impinged on a renal
e proximal aspect of the graft material with respect tochym
Cau
too
at pro
enal i
anas
belo
ngest
r post
o hem
impin
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boliz
nal ar
verag
nal ar
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belo
verag
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intervention not appearing on the aforementioned tables or
figures recurrent stenosis developed in a renal stent that was
placed before endograft deployment. The in-stent resteno-
sis was subsequently treated with renal artery angioplasty
Fig 6. Series of images illustrates the case of a patient
A, After the initial procedure both renal arteries were pate
B, Three hours after the procedure anuria developed; re
partial coverage of the renal ostia. The patient was brough
from a brachial approach. The renal arteries demonstrate
was accomplished, and stents were placed within the ren225 days after endograft implantation, with balloon angio-
plasty and placement of a renal stent in the contralateral
artery to address worsening preexisting renal stenosis.
Seven patients (ZSR, 1; SSR, 1; ZHR, 5) required
dialysis after aneurysm repair, because of worsening of
underwent endovascular repair with the Zenith device.
though difficult to visualize with a portable imaging unit.
ctive assessment of intraoperative images demonstrated
n interventional suite, where an angiogram was obtained
ow on this image. C and D, Access to each renal artery
ia to push the fabric down slightly.who
nt, al
trospe
t to a
no fl
al ost
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atheroembolism (ZSR, 1), unintentional coverage of a
renal artery (ZHR, 1), intentional coverage of an accessory
renal artery and subsequent development of thrombotic
thrombocytopenic purpura (ZHR, 1), multiple system or-
gan failure (SSR, 1), or prolonged hypotension (ZHR, 1).
The incidence of renal failure requiring dialysis did not
differ between the ZSR and SSR groups (P  .49).
DISCUSSION
Renal morbidity ranks third in incidence of undesirable
outcome after open1 and endovascular aneurysm repair,8
and remains a predictor of diminished long-term survival.2
Several causes of renal dysfunction contribute to morbidity
in patients undergoing aneurysm repair. Open repair has
been plagued by atheroemboli, clamp-related renal isch-
emia, technical issues pertaining to the renal arteries (eg,
dissection, occlusion), and multiple system organ failure as
potential causes for development of renal insufficiency.
Contrast material–induced nephropathy must be added to
the list of potential causes for morbidity in patients who
have undergone endovascular repair. Suprarenal stent-graft
fixation adds to the complexity of the evaluation. Although
some have postulated deleterious effects of such a stent
potentially traversing a renal ostia, several reports attest to
the safety of such practice.15-25 Two studies failed to detect
any difference between suprarenal versus infrarenal fixation
with respect to renal function,16,26 and one study reported
a moderate incidence of acute renal dysfunction.21 How-
ever, the effect of such a stent on the dynamic aspects of
arterial flow into the renal artery has not been determined
over the long term, but has been evaluated experimentally
Fig 6 (continued). E, Final angiogram shows unobstructed renal
blood flow bilaterally. The patient had a transient rise in serum
creatinine concentration, which was normal at the 30-day
follow-up visit.and mathematically modeled where investigators postu-
lated a potential for increased turbulence without signifi-
cant flow reduction.27
Despite a clear definition for assessment of anatomic
renal abnormalities, there is little agreement when attempt-
ing to define renal dysfunction. Previous reports of pro-
spective multicenter endograft trials5,6,28 have not detailed
the effect of the procedure or the prosthesis on renal
function, nor is a method of renal function assessment
defined in the revised reporting standards for endovascular
aneurysm repair document.29 However, historically, renal
insufficiency has been defined in several ways.30 We chose
to use the simplest method of renal function assessment
(SCr) as the primary means of screening, in an effort to
maximize study compliance while maintaining relatively
high sensitivity for detection of renal abnormalities by using
an extremely low threshold value (increase of baseline value
in excess of 30%). Further data analyses for all patients were
performed in an attempt to account for the effects of
weight, gender, and age, with use of calculated creatinine
clearance. Amidst the arguments between the sensitivity of
SCr versus creatinine clearance for detection of renal insuf-
ficiency after aneurysm repair, the most appropriate for-
mula used to calculate creatinine clearance in the absence of
24-hour urine collection is also debated.11 We chose to use
the Cockcraft-Gault formula,14 understanding the de-
scribed error of up to 35% when compared with true
assessment of glomerular filtration rate or direct measure-
ment of creatinine clearance.11
The initial superiority of renal function in the ZSR
group at hospital discharge did not extend through 12
months, nor was it significant after removal of patients with
suprarenal clamps from the SSR group. In fact, creatinine
clearance plots for the SSR and ZSR groups were nearly
identical through 12 months. The overall deterioration in
renal function in the ZSR group stabilized at 12 months; no
data for the SSR group are available beyond 12 months.
The cause of renal deterioration during the first year is
speculative, but may have resulted from repeated adminis-
tration of iodinated contrast material (four CT scans and
the implantation procedure), late manifestation of proce-
dural atheroemboli, or continued renal injury from the
suprarenal stent. Although it is difficult to determine a
definitive cause for the observed renal dysfunction, it would
seem logical to attempt to limit the number of contrast-
enhanced studies in the first year. Potentially an early CT
scan, either the pre-discharge or 30-day study, may be
eliminated, and the 6-month evaluation may not be neces-
sary in the setting of a satisfactory result from the initial
study. Contrast administration may be supplanted by use of
alternative imaging methods, such as duplex ultrasonogra-
phy and non-contrast–enhanced CT.
The improved renal function between 12 and 24
months without any new observation of additional ana-
tomic events makes it difficult to implicate the suprarenal
stent as a factor for any persistent effect on renal dysfunc-
tion. The improvement in creatinine clearance between 12
and 24 months is reassuring that the downward trend after
JOURNAL OF VASCULAR SURGERY
June 20041226 Greenberg et alendovascular (and possibly open) repair will, at a minimum,
become stabilized. If repeated contrast administration is
partially responsible for the renal dysfunction, use of less
nephrotoxic contrast agents31 or other medications has the
potential to limit the renal affects of contrast administra-
tion.32-35
Placement of graft material in close proximity to the
renal arteries has been advocated to maximize the length of
proximal neck coverage possibly improving the seal and
overall fixation. Additional precision with this delivery sys-
tem may have resulted in an overaggressive approach in
some cases. Of the 351 implantations, nine patients were
noted to have graft material impinging on renal ostia. When
noted and treated at the time of initial implantation, no late
renal sequelae occurred. When compared with the renal
dysfunction associated with untreated graft impingement
on the renal artery, the importance of careful post-proce-
dure assessment of renal artery status is underscored (Fig 5,
A-E). Renal access through the suprarenal component (Fig
7) of the endoprosthesis has not been a significant issue,
and did not prohibit treatment in any case. The single
Fig 7. Access to a secondary renal branch was accomplished via a
brachial approach through the suprarenal stent. Note the two
0.014-inch wires, one in each of the primary renal branches. These
were used to introduce balloons for balloon dilation of the stenosis
with the kissing balloon technique.patient who received treatment of recurrent renal stenosis
and contralateral de novo stenosis highlights several impor-
tant considerations regarding the use of this prosthesis in
patients with renal arterial disease. Renal artery stenting can
be performed before, during, or after endovascular aneu-
rysm repair when clinically indicated. However, stents that
protrude more than 1 to 2 mm into the aorta may prevent
the suprarenal component from lying flush against the
aortic wall. The effect of such distortion has not been
assessed. Many investigators prefer to place renal stents at
the time of aneurysm treatment or after endovascular re-
pair. Access to the renal artery may be established through
the main body of the device before complete deployment of
the suprarenal component (Fig 8; this implies a modifica-
tion of the deployment instructions described in the man-
Fig 8. Cobra 2 catheter access to a renal artery can be accom-
plished before complete deployment of the uncovered suprarenal
stent. To achieve this, the top stent is partially deployed, and
through the contralateral limb a wire is guided through the struts
of the top stent.
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femoral or brachial approach. Complex renal anatomy,
particularly in the setting of inferior angulation of the renal
artery, and situations where graft material is covering a
significant portion of the renal ostia are likely better han-
dled via brachial access. It is critical to evaluate the position
of the graft material with respect to the renal arteries during
the deployment procedure and on the completion angio-
gram.
Hemodialysis was rarely required after treatment of
AAA, being necessary in six patients in the endovascular
treatment group and one patient in the surgical treatment
group. However, patients in the endovascular group who
ultimately required dialysis tended to be at high physiologic
risk (5 of 6 patients), and need for dialysis was associated
with contributing factors such as preexisting chronic renal
insufficiency, technical problems with deployment in which
stent graft material impaired renal blood flow, or the pres-
ence of other significant comorbid conditions.
The desire to fixate endovascular grafts in the suprare-
nal aorta mandates placement of a transrenal stent. Despite
an increase in SCr and decrease in creatinine clearance over
12 months in both open and endovascular patient groups,
any observed deterioration in renal function in the endo-
vascular group stabilizes or improves thereafter. The cause
of the renal insult in both groups remains unclear. The
absence of detectable new renal artery infarctions or occlu-
sions after 12 months in conjunction with stabilization or
improvement in creatinine clearance between 12 and 24
months support the absence of a sustained source of renal
injury. Thus transrenal fixation appears to be safe through
the intermediate follow-up period. A careful assessment of
the proximal aspect of the graft material with respect to the
renal ostia remains a critical portion of the procedure, and is
fundamental to preservation of normal renal function. Any
impingement of graft material on the renal artery should be
treated at initial device implantation.
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at www.mosby.com/jvs.DISCUSSIONDr Jon Matsumura (Chicago, Ill). I believe that suprarenal
stenting is probably pretty safe, but if you wanted to prove it to me
you would need to do more than serum creatinines. There has to
be direct imaging of the renal artery. You mentioned core lab and
imaging, but I think most of that is probably CT and plain film. For
how many of the 200 standard-risk patients did the core lab get an
angiogram or a duplex of the renal arteries? How many patients
had a site reading of a test demonstrating patency of the renal
arteries?
Dr Roy Greenberg. As you know, the core lab actually
analyzes the CT and KUB studies but these aren’t coupled with any
clinical information. The lab may receive supplemental data, but
does not have a routine method of integrating any supplemental
information with the standard imaging modalities. Thus, it would
not be capable of determining how many people are developing
renal artery stenosis or whether that renal artery stenosis is becom-
ing significant. Adverse events that were charted during the study
included any increase in creatinine as well as an increase in medi-
cation required to treat hypertension. I can tell you that there was
no incidence of clinically significant renal artery stenosis develop-
ing during the study that we were able to detect.
Dr Peter Gloviczki (Rochester, Minn). We had a couple of
patients with AneuRx grafts in whom we thought we put the graft
correctly and it migrated, but we thought more proximally; the
tip-off was a couple of weeks later when this patient had elevated
creatinine and then came back and we could stent the renal arteries
and salvage it. The question is, what is the protocol you follow for
this type of patients because maybe when you check your first
creatinine it may be too late. That’s the first thing. The second is,
do you believe that there is proximal migration of endografts at all?
Dr Greenberg. In answer to the first question, I think that if
you are comfortable with your postprocedure angiogram and you
are certain that the graft material is below the renal arteries, there
should be a very low, if any, incidence of cranial migration. The
reason I say that is because migration was a separate end point that
was studied here and it was specifically analyzed, using a fairly
complex method of charting the position of the suprarenal stent
with respect to the SMA. During the course of that assessment six
migrations were detected and all of those migrations were caudal.
Over the 24-month period there were no cranial migrations and
every single renal artery event could be attributed by retrospective
assessment to the initial procedure, in which the defect was iden-
tifiable.
Dr Gloviczki. The serum creatinine.
Dr Greenberg. The serum creatinine, I agree with you.
Technically, with any type of endovascular graft, if you have put the
graft material over the renal artery, there is a likelihood that you
may miss it because the patient is heparinized, the renal arteriesdon’t thrombose at that time and you have missed the ball game
there. So I agree, serum creatinine is a late marker and you are
probably doing damage if that’s what you are using as your
indication for a renal problem. You need to be accurate with your
procedural angiographic interpretations.
Dr Mark Adams (Milwaukee, Wis). I’m curious how many
patients with diabetes were in each group since obviously diabetics
were much more sensitive to the contrast used to endovascular
approach.
Dr Greenberg. Only a small percentage of the patients in the
study had insulin-dependent diabetes. I can’t break that down; I
don’t know offhand.
Dr Adams. Type 2 diabetes?
Dr Greenberg. Insulin-dependent diabetes. I don’t know the
breakdown of that.
Dr James McKinsey (Chicago, Ill). I think the study brings
up two other questions that you alluded to in your conclusion.
Have you compared those patients who have infrarenal endografts
with those with suprarenal fixation rather than the standard oper-
ative control, and then as a second control have you looked at
patients who did not undergo any procedure but were in the same
high-risk atherosclerotic group that CSR patients are in? Are we
just seeing a natural trend from our patients or is this a contrast or
a graft-related phenomenon?
Dr Greenberg. Well, with respect to your first question, we
did not compare these results with any patients with infrarenal
endografts. The study design was really a prospective concurrent
control study, and this analysis was intended only to assess a device
with a suprarenal component. If this becomes a particular area of
interest, I think the only way that we would be able to differentiate
the grafts would be a randomized trial because the incidence of
renal dysfunction in both of these groups I would anticipate to be
very low. We would need a lot of patients and a long follow-up.
Dr McKinsey. Are we looking at this drop in renal function?
Dr Greenberg. Both groups of patients have a decrease in
their creatinine clearance and an increase in their serum creatinine
through 12 months that is almost identical. Why that occurs and
why it gets better between 12 and 24 months makes me think that
it is something that we are doing during the interim. I don’t think
this is a late appearance of renal dysfunction. I think that a lot of it
has to do with repeated contrast dosing in the endovascular group,
and the message I took from this is to try and limit the number of
CT scans, so rather than get a discharge and a 30-day CAT scan,
you get one CAT scan in that period. If the CAT scan looks good
and you have good anatomy, maybe you avoid the 6-month CAT
scan, so you really try and limit those areas and perhaps that’s an
avenue for looking at duplex ultrasound as a follow-up as well.
